ID | 62296 |
フルテキストURL | |
著者 |
Maruyama, Masato
Department of Anatomy and Brain Science, Kansai Medical University
Nakano, Yousuke
Department of Anatomy and Brain Science, Kansai Medical University
Nishimura, Takuya
Department of Anatomy and Brain Science, Kansai Medical University
Iwata, Ryoichi
Department of Neurosurgery, Kansai Medical University
Matsuda, Satoshi
Department of Cell Signaling, Institute of Biomedical Science, Kansai Medical University
Hayashi, Mikio
Department of Physiology, Kansai Medical University
Nakai, Yuki
Department of Anatomy and Brain Science, Kansai Medical University
Nonaka, Masahiro
Department of Neurosurgery, Kansai Medical University
Sugimoto, Tetsuo
Department of Anatomy and Brain Science, Kansai Medical University
|
抄録 | Glioblastoma multiforme (GBM) is the most prevalent malignant primary brain tumor with a high recurrence rate. Despite multimodal therapy including surgical resection, chemotherapy, and radiotherapy, the median survival time after the initial diagnosis of GBM is approximately 14 months. Since cancer stem cells (CSCs) are considered the leading cause of cancer recurrence, glioblastoma stem cell-targeted therapy is a promising strategy for the treatment of GBM. However, because CSC heterogeneity has been implicated in the difficulties of CSC-target therapy, more in-depth knowledge of CSC biology is still required to develop novel therapies. In this study, we established single cell-derived tumorspheres from human glioblastoma U87MG cells. One of these tumorspheres, P4E8 clone, showed CSC-like phenotypes, such as self-renewal capacity, expression of CSC markers, resistance to anti-cancer agents, and in vivo tumorigenicity. Therefore, we used P4E8 cells as a cell-based model of glioblastoma stem cells (GSCs). Gene expression analysis using microarray indicated that the most highly expressed genes in P4E8 cells compared to the parental U87MG were PC3-secreted microprotein (MSMP). Furthermore, MSMP was expressed in patient-derived GSCs and human glioma tissues at the protein level, implying that MSMP might contribute to glioma development and progression.
|
発行日 | 2021-07
|
出版物タイトル |
Biological and Pharmaceutical Bulletin
|
巻 | 44巻
|
号 | 7号
|
出版者 | Pharmaceutical Society of Japan
|
開始ページ | 910
|
終了ページ | 919
|
ISSN | 0918-6158
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2021 The Pharmaceutical Society of Japan
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1248/bpb.b20-00868
|
助成機関名 |
Japan Society for the Promotion of Science
Kansai Medical University
|
助成番号 | 25460049
17K07183
|